WST Stock Forecast & Price Target

West Pharmaceutical Servs is well positioned because its Q3 results showed broad-based HVP momentum, with HVP Components up 20% organically to 53% of revenue and GLP-1-related components still growing well into the 30s%, while non-GLP-1 HVP grew in the high teens, signaling durable demand beyond any single molecule. Stronger mix, pricing, utilization, and SG&A leverage lifted gross margin to 39.7% and adjusted operating margin to 25.3%, and management sees Annex-1 upgrades, automation, debottlenecking, and capacity optimization as multiyear drivers that can support about 200 bps of annual organic growth through the end of the decade. Even with the SmartDose divestiture creating a 290-bp headwind to FY27 reported growth, the company’s diversified exposure across biologics, GLP-1s, and injectable delivery systems supports a higher-quality earnings profile and continued margin expansion.

West Pharmaceutical Servs is facing a softer fundamental setup because West Vantage declined 6.6% organically as CGM programs rolled off, and the overlap of legacy roll-offs with new-program ramps is likely to mute reported segment growth through 2027. The company still benefits from a healthy funnel and higher-value drug-handling contracts, but slower conversion, weaker capacity utilization, or a shift toward oral GLP-1 alternatives could reduce the mix benefit from high-margin elastomer components and pressure gross margin leverage. Additional downside comes from geopolitical risk across 25 manufacturing facilities, customer de-stocking, product recall exposure, and the risk of multiple compression if growth or margins disappoint.